Ubi Titer Issue #2
Why Kinetics and Costimulation Beat Maximum Affinity
Kinetic tuning and costimulatory context beat affinity maximization — two papers, two different mechanisms, the same lesson
- antibody affinity
- CD2 costimulation
- ADC resistance
- formulation
- pharmacokinetics
What this issue covers
- 1.Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors
Non-blocking HER2×CD2 bispecific + EpCAM×CD3 TCE: 8/9 complete remissions vs 1/9 with TCE alone. Lower cytokine release than HER2×CD28 approach. Provides costimulation to CD28-negative CD8 T cells.
- 2.First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer
117 heavily pre-treated NSCLC patients, 19% ORR (29% taxane-naive nonsquamous), 11.3-month median DOR. IB6 expressed in 92% of biopsies. First JCO readout for an IB6-directed ADC.
- 3.Discovery and optimization of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor for the treatment of hemophilia A and B
Phage + hybridoma screen → TFPI-blocking mAb optimized to ~5.72 nM affinity for PK (not the tightest binder). Now FDA-approved as Hympavzi. Case study in deliberate affinity de-optimization as a PK lever.
- 4.NMR detects clustering and ultra-weak excipient interactions governing monoclonal antibody viscosity in formulation-relevant conditions
NMR + DLS + rheometry at 50–150 mg/mL: arginine/lysine suppress mAb clustering; proline/glycine promote it. Sucrose binds antibody but doesn't reduce viscosity. Mechanistic pipeline for SC formulation decisions.
- 5.Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer
AKR1C1 binds NECTIN4 and blocks AP2M1-dependent clathrin endocytosis; WWP2 exports ADC via extracellular vesicles. High NECTIN4 expression + defective uptake = resistance to enfortumab vedotin. AKR1C1 inhibition restores sensitivity preclinically.
Paper 1 · mAbs
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors
Non-blocking HER2×CD2 bispecific + EpCAM×CD3 TCE: 8/9 complete remissions vs 1/9 with TCE alone. Lower cytokine release than HER2×CD28 approach. Provides costimulation to CD28-negative CD8 T cells.
Core finding
A non-blocking anti-CD2 antibody was engineered into a HER2×CD2 bispecific that, combined with an EpCAM×CD3 T cell engager at sub-toxic doses, produced complete tumor remission in 8 of 9 mice — compared to 1 of 9 with the TCE alone. Cytokine release was markedly lower than a HER2×CD28 bispecific comparator, while anti-tumor activity was comparable. The CD2 approach delivers costimulation to CD28-negative CD8 T cells, a significant population in elderly patients and solid tumors where CD28-targeted strategies fail.
What is novel
First demonstration of CD2-directed costimulatory bispecific in combination with CD3 TCE for solid tumors. The non-blocking CD2 antibody preserves TCR function while adding signal 2. CD28-independent costimulation of CD8 T cells has been underexplored as a rescue strategy for solid tumor TCE programs.
Limitations
Fully preclinical xenograft models; does not recapitulate tumor-immune microenvironment. HER2 and EpCAM are proof-of-concept targets, not a proposed clinical pairing. Manufacturing complexity of co-administering two bispecifics is not addressed.
Why it matters in context
CD3 T cell engagers have largely failed in solid tumors due to dose-limiting cytokine toxicity and insufficient costimulation. Papers combining TCEs with costimulatory arms (CD28, 4-1BB, IL-2) are multiplying; CD2 is a less-traveled path that sidesteps CD28-related toxicity concerns. Tarlatamab is the only approved solid-tumor TCE to date.
Paper 2 · Journal of Clinical Oncology
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer
117 heavily pre-treated NSCLC patients, 19% ORR (29% taxane-naive nonsquamous), 11.3-month median DOR. IB6 expressed in 92% of biopsies. First JCO readout for an IB6-directed ADC.
Core finding
Sigvotatug vedotin (anti-integrin beta-6, MMAE payload) was evaluated across three dosing regimens in 117 advanced NSCLC patients (median 3 prior systemic therapies; 96% prior platinum, 91% prior PD-1/L1 inhibitor). Overall ORR 19%, 11.3-month median DOR. Taxane-naive nonsquamous subset: 29% ORR. IB6 expression detected in 92% of evaluable biopsies regardless of histology. Optimal regimen: 1.8 mg/kg adjusted ideal body weight Q2W.
What is novel
First peer-reviewed Phase I dose-expansion readout validating IB6 as an ADC target in NSCLC. The 11.3-month median DOR in this heavily pre-treated, post-immunotherapy population is a clinically meaningful signal. IB6 expression uniformity (92%) across histologies suggests a broad biomarker-selected population.
Limitations
Phase I, single-arm, no comparator. Heavily pre-treated, performance-status-filtered population reduces generalizability. MMAE payload; increasing clinical preference for TOP1i payloads not addressed.
Why it matters in context
NSCLC ADC landscape is crowded: TROP2, HER2, MET, Nectin-4, B7-H4. IB6 offers distinct biology — expressed in tumor cells including squamous histology where other targets are sparse. JCO publication reflects confidence in the signal.
Paper 3 · mAbs
Discovery and optimization of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor for the treatment of hemophilia A and B
Phage + hybridoma screen → TFPI-blocking mAb optimized to ~5.72 nM affinity for PK (not the tightest binder). Now FDA-approved as Hympavzi. Case study in deliberate affinity de-optimization as a PK lever.
Core finding
Hybridoma and phage display screens identified anti-TFPI antibodies blocking the TFPI-FXa interaction via the TFPI K2 domain. High-affinity candidates showed rapid clearance due to target-mediated drug disposition. The optimized candidate, marstacimab at ~5.72 nM affinity, achieved durable plasma circulation while maintaining hemostatic efficacy. CDR-grafted humanization followed by affinity adjustment — not maximization — produced the clinical candidate now approved as Hympavzi.
What is novel
Retrospective discovery narrative for an approved drug providing a concrete case study in deliberate affinity de-optimization for PK benefit. The specific antibody engineering path — from screen to affinity tuning — is documented comprehensively for the first time.
Limitations
Retrospective publication on an already-approved drug; the novel contribution is the engineering narrative, not a new principle. Generalizability depends on TMDD kinetics for the target of interest.
Why it matters in context
Hemophilia non-factor replacement therapies are an active class: emicizumab, fitusiran, marstacimab. The affinity-PK tradeoff lesson applies broadly to any mAb with significant target-mediated clearance.
Paper 4 · mAbs
NMR detects clustering and ultra-weak excipient interactions governing monoclonal antibody viscosity in formulation-relevant conditions
NMR + DLS + rheometry at 50–150 mg/mL: arginine/lysine suppress mAb clustering; proline/glycine promote it. Sucrose binds antibody but doesn't reduce viscosity. Mechanistic pipeline for SC formulation decisions.
Core finding
NMR spectroscopy combined with rheometry and DLS reveals how common excipients modulate mAb viscosity at clinically relevant concentrations. Arginine and lysine substantially reduce self-assembly and viscosity. Proline and glycine promote clustering. Sucrose binds antibody surface sites — confirmed by NMR — but does not reduce viscosity, showing that excipient-mAb binding is necessary but not sufficient.
What is novel
First systematic NMR-based pipeline for excipient-mAb interaction characterization at formulation-relevant concentrations. The sucrose finding — binding without viscosity reduction — resolves a long-standing formulation paradox. Provides mechanistic grounding for empirical excipient rankings previously established by rheometry alone.
Limitations
Single antibody characterized in depth; generalizability to other mAb charge profiles requires validation. NMR at high protein concentrations is technically demanding and not yet suitable for high-throughput screening.
Why it matters in context
High-concentration formulation for subcutaneous delivery is a major bottleneck for biologics. Prior work ranked excipients empirically; this paper provides the first mechanistic picture using NMR. The arginine/lysine superiority over proline is now mechanistically grounded.
Paper 5 · Cancer Cell
Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer
AKR1C1 binds NECTIN4 and blocks AP2M1-dependent clathrin endocytosis; WWP2 exports ADC via extracellular vesicles. High NECTIN4 expression + defective uptake = resistance to enfortumab vedotin. AKR1C1 inhibition restores sensitivity preclinically.
Core finding
In urothelial carcinoma tumors resistant to enfortumab vedotin (NECTIN4-ADC), a cell subpopulation maintains high NECTIN4 surface expression while showing defective ADC internalization. AKR1C1 physically binds NECTIN4 and disrupts AP2M1-dependent clathrin-mediated endocytosis; the AKR1C1-WWP2 axis simultaneously promotes extracellular vesicle-mediated export of ADC payload. Pharmacologic AKR1C1 inhibition restores internalization and drug sensitivity in patient-derived preclinical models.
What is novel
Mechanistically resolves the high-antigen/resistant phenotype paradox. AKR1C1 is a new resistance gene for the ADC field, not previously implicated in NECTIN4 trafficking. Paired spatial transcriptomics before and after treatment enables the subpopulation identification that bulk sequencing would miss.
Limitations
Urothelial carcinoma-specific study; AKR1C1 resistance mechanism may not generalize to other ADC targets or tumor types. AKR1C1 inhibitor combination strategy is preclinical only with no dose-optimization or toxicity data. Spatial transcriptomics is resource-intensive and not routine in clinical trial design.
Why it matters in context
The PNAS CTC paper (June 19 issue) showed at the clinical level that receptor expression does not predict ADC response; this Cancer Cell paper now explains the mechanism — defective endocytic trafficking in a high-antigen subpopulation. Together they make the case that ADC biomarker strategy needs to incorporate endocytic competence, not just receptor IHC.
Primary papers
- [1] Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors (mAbs)
- [2] First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer (Journal of Clinical Oncology)
- [3] Discovery and optimization of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor for the treatment of hemophilia A and B (mAbs)
- [4] NMR detects clustering and ultra-weak excipient interactions governing monoclonal antibody viscosity in formulation-relevant conditions (mAbs)
- [5] Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer (Cancer Cell)